January 22, 2026 09:29 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Twist before Tamil Nadu polls! TTV Dhinakaran returns to NDA after bitter exit | Gold goes berserk! Prices smash all-time high as global tensions explode | Markets end in red: Sensex slips 271 points, Nifty below 25,200; rupee hits record low | Nitin Nabin becomes BJP’s youngest president ahead of key assembly polls, PM Modi calls him ‘my boss’ | Viral video scandal rocks Karnataka Police: DGP Ramachandra Rao suspended | Jolt to ECI over SIR! SC allows BLAs at hearing, questions 'logical discrepancy'; TMC declares 'BJP's game over' | Will dal disrupt diplomacy? US lawmakers urge Trump to act on India’s 30% pulse tariff | 'Pakistan deserves Operation Sindoor 2.0', says Baloch leader over Trump’s Gaza board invitation to Islamabad | From Malda to the nation: PM Modi unveils India’s Vande Bharat sleeper | War zone Beldanga: Highway blocked, reporters attacked in migrant death protests
Stock Market
Representational Photo: ChatGPT

Bloodbath on Dalal Street! Sensex crashes over 700 points, Nifty down 200 points amid market panic

| @indiablooms | Jan 08, 2026, at 02:08 pm

Mumbai/IBNS: The Indian stock market witnessed a sharp sell-off on Thursday, with the BSE Sensex plummeting over 700 points and the NSE Nifty 50 sliding more than 200 points, media reports said.

The indices remained under pressure throughout the morning session, with Sensex touching an intraday low of 84,230.

Among the notable laggards in the Nifty 500 were Signature Global, Hindustan Zinc, National Aluminium, NMDC, Hindustan Copper, JSL and GMDC.

At around 1:30 pm, Punjab National Bank shares fell 2.13%, while Apex Frozen Foods plunged 7.56%, intensifying the market slide.

In the morning, shares of Panacea Biotec Ltd. surged around 9 per cent on Thursday after the pharmaceutical and vaccine maker announced the completion of enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll.

The company has enrolled a total of 10,335 participants in the late-stage trial, marking a key milestone in the development of India’s indigenous dengue vaccine.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm